vorinostat has been researched along with Cancer of Skin in 55 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat is a small molecule inhibitor of class I and II histone deacetylases with preclinical activity in melanoma." | 9.19 | Phase II trial of vorinostat in advanced melanoma. ( Adams, PD; Alpaugh, RK; Haas, NB; Hotte, S; Litwin, S; Martin, LP; McBryan, T; McWhirter, E; Oza, A; Polintan, R; Quirt, I; vonMehren, M; Wang, L; Zweibel, J, 2014) |
| "A phase I study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of the oral histone deacetylase (HDAC) inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL)." | 9.16 | Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma. ( Hamada, T; Iwatsuki, K; Kato, Y; Noguchi, K; Shimamoto, T; Sugaya, M; Tobinai, K; Tsuboi, R; Wada, H, 2012) |
| "Vorinostat, an orally active histone deacetylase inhibitor, was approved in October 2006 by the US Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease during or after treatment with 2 systemic therapies." | 9.14 | Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. ( Abuav, R; Boileau, K; Breneman, D; Chen, C; Duvic, M; Geskin, LJ; Gunchenko, A; Olsen, EA; Pacheco, TR; Parker, S; Ricker, JL; Rizvi, S; Sanz-Rodriguez, C; Vonderheid, EC, 2009) |
| "To evaluate the activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in persistent, progressive, or recurrent mycosis fungoides or Sézary syndrome (MF/SS) cutaneous t-cell lymphoma (CTCL) subtypes." | 9.12 | Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. ( Arduino, JM; Chen, C; Duvic, M; Foss, FM; Frankel, SR; Kim, YH; Kuzel, TM; Olsen, EA; Pacheco, TR; Parker, S; Ricker, JL, 2007) |
| "The pharmacology, pharmacokinetics, clinical efficacy, safety, adverse effects, dosage and administration, and role in therapy of vorinostat in the treatment of cutaneous T-cell lymphoma (CTCL) are reviewed." | 8.86 | Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. ( Kavanaugh, SA; Kavanaugh, SM; Kolesar, JM; White, LA, 2010) |
| "We describe a 34-year-old Japanese man with syringotropic CD8+ mycosis fungoides (MF) accompanied by hypohidrosis who was treated with vorinostat and retinoids." | 7.79 | Successful treatment of syringotropic CD8+ mycosis fungoides accompanied by hypohidrosis with vorinostat and retinoids. ( Aiba, S; Fujimura, T; Kakizaki, A; Kambayashi, Y; Mizuashi, M; Watabe, A, 2013) |
| "Vorinostat (suberoylanilide hydroxamic acid, SAHA), an inhibitor of class I and II histone deacetylases, has been approved for the treatment of cutaneous T-cell lymphoma." | 7.76 | Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. ( Aparicio, CB; Bischoff, JR; de La Cueva, P; Herrera, M; Herreros, B; Longo, MI; Martin-Perez, D; Martínez Leal, JF; Ortiz-Romero, PL; Piris, MA; Rodriguez, ME; Villuendas, R; Wozniak, MB, 2010) |
| "Vorinostat is a histone deacetylase inhibitor that induces differentiation, growth arrest, and/or apoptosis of malignant cells both in vitro and in vivo and has shown clinical responses in approximately 30% of patients with advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma (CTCL)." | 7.74 | Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. ( Fantin, VR; Frankel, SR; Gooden, F; Harrington, EA; Hendrickson, RC; Hou, XS; Kadin, ME; Korenchuk, S; Li, L; Loboda, A; Paweletz, CP; Pierce, JW; Randolph, S; Reilly, JF; Richon, VM; Roth, JA; Ware, CM, 2008) |
| " We report on a 51-year-old patient with tumor-stage mycosis fungoides who developed several unusual features such as extensive necrosis of lymphoma lesions, granulomatous reaction, and venular thromboses while under treatment with bexarotene, vorinostat, and high-dose fenofibrate." | 7.74 | Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. ( Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W, 2008) |
| "Vorinostat is a small molecule inhibitor of class I and II histone deacetylases with preclinical activity in melanoma." | 5.19 | Phase II trial of vorinostat in advanced melanoma. ( Adams, PD; Alpaugh, RK; Haas, NB; Hotte, S; Litwin, S; Martin, LP; McBryan, T; McWhirter, E; Oza, A; Polintan, R; Quirt, I; vonMehren, M; Wang, L; Zweibel, J, 2014) |
| "A phase I study was conducted to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of the oral histone deacetylase (HDAC) inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL)." | 5.16 | Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma. ( Hamada, T; Iwatsuki, K; Kato, Y; Noguchi, K; Shimamoto, T; Sugaya, M; Tobinai, K; Tsuboi, R; Wada, H, 2012) |
| "Vorinostat, an orally active histone deacetylase inhibitor, was approved in October 2006 by the US Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease during or after treatment with 2 systemic therapies." | 5.14 | Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. ( Abuav, R; Boileau, K; Breneman, D; Chen, C; Duvic, M; Geskin, LJ; Gunchenko, A; Olsen, EA; Pacheco, TR; Parker, S; Ricker, JL; Rizvi, S; Sanz-Rodriguez, C; Vonderheid, EC, 2009) |
| "To evaluate the activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in persistent, progressive, or recurrent mycosis fungoides or Sézary syndrome (MF/SS) cutaneous t-cell lymphoma (CTCL) subtypes." | 5.12 | Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. ( Arduino, JM; Chen, C; Duvic, M; Foss, FM; Frankel, SR; Kim, YH; Kuzel, TM; Olsen, EA; Pacheco, TR; Parker, S; Ricker, JL, 2007) |
| "Vorinostat is a histone deacetylase inhibitor used in the treatment of recurrent or persistent cases of cutaneous T-cell lymphoma (CTCL)." | 4.88 | QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. ( Lynch, DR; Newby, LK; Washam, JB, 2012) |
| "The pharmacology, pharmacokinetics, clinical efficacy, safety, adverse effects, dosage and administration, and role in therapy of vorinostat in the treatment of cutaneous T-cell lymphoma (CTCL) are reviewed." | 4.86 | Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. ( Kavanaugh, SA; Kavanaugh, SM; Kolesar, JM; White, LA, 2010) |
| "We describe a 34-year-old Japanese man with syringotropic CD8+ mycosis fungoides (MF) accompanied by hypohidrosis who was treated with vorinostat and retinoids." | 3.79 | Successful treatment of syringotropic CD8+ mycosis fungoides accompanied by hypohidrosis with vorinostat and retinoids. ( Aiba, S; Fujimura, T; Kakizaki, A; Kambayashi, Y; Mizuashi, M; Watabe, A, 2013) |
| "Vorinostat (suberoylanilide hydroxamic acid, SAHA), an inhibitor of class I and II histone deacetylases, has been approved for the treatment of cutaneous T-cell lymphoma." | 3.76 | Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. ( Aparicio, CB; Bischoff, JR; de La Cueva, P; Herrera, M; Herreros, B; Longo, MI; Martin-Perez, D; Martínez Leal, JF; Ortiz-Romero, PL; Piris, MA; Rodriguez, ME; Villuendas, R; Wozniak, MB, 2010) |
| "Vorinostat is a histone deacetylase inhibitor that induces differentiation, growth arrest, and/or apoptosis of malignant cells both in vitro and in vivo and has shown clinical responses in approximately 30% of patients with advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma (CTCL)." | 3.74 | Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. ( Fantin, VR; Frankel, SR; Gooden, F; Harrington, EA; Hendrickson, RC; Hou, XS; Kadin, ME; Korenchuk, S; Li, L; Loboda, A; Paweletz, CP; Pierce, JW; Randolph, S; Reilly, JF; Richon, VM; Roth, JA; Ware, CM, 2008) |
| " We report on a 51-year-old patient with tumor-stage mycosis fungoides who developed several unusual features such as extensive necrosis of lymphoma lesions, granulomatous reaction, and venular thromboses while under treatment with bexarotene, vorinostat, and high-dose fenofibrate." | 3.74 | Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. ( Assaf, C; Beyer, M; Lukowsky, A; Roewert-Huber, J; Steinhoff, M; Sterry, W, 2008) |
| "Bexarotene was investigated in one trial each with vorinostat, methotrexate or gemcitabine, whereby only methotrexate possibly enhanced the effect of bexarotene." | 2.50 | Systematic review of combination therapies for mycosis fungoides. ( Beyer, M; Erdmann, R; Humme, D; Nast, A; Vandersee, S, 2014) |
| "The cause of mycosis fungoides is unknown and, with the possible exception of very early stage disease, no cure is available." | 2.43 | Treatment of cutaneous T-cell lymphoma/mycosis fungoides. ( Bradley, B; Parker, SR, 2006) |
| "This study was conducted to identify novel therapeutic targets that can be combined with HDACis for treating CTCL." | 1.62 | Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma. ( Fujii, K; Jimura, N; Kanekura, T; Kondo, T; Qiao, Z; Tsuchiya, R; Yoshimatsu, Y, 2021) |
| "With vorinostat treatment, the best response was partial remission in 5 patients (33%) and stabilization in 4 patients (27%)." | 1.42 | Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients. ( Brocard, A; Dréno, B; Knol, AC; Kogge, A; Peuvrel, L; Quéreux, G; Renaut, JJ; Saint-Jean, M; Volteau, C, 2015) |
| "Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL)." | 1.42 | Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. ( Benoit, BM; Cedeno-Laurent, F; Kim, EJ; Rook, AH; Singer, EM; Vittorio, CC; Wysocka, M; Yosipovitch, G, 2015) |
| "Vorinostat is a potent HDAC inhibitor and has shown potential to inhibit growth of human xenograft tumors." | 1.39 | Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. ( Athar, M; Ballestas, ME; Chaudhary, SC; Elmets, CA; Kopelovich, L; Kurundkar, D; Srivastava, RK, 2013) |
| "Poikilodermatous mycosis fungoides is a rare form of cutaneous T-cell lymphoma that is characterized clinically by localized or diffuse patches, which consist of telangiectases, mottled hyper- and hypopigmentation, and atrophy." | 1.36 | Poikilodermatous mycosis fungoides. ( Farley-Loftus, R; Latkowski, JA; Mandal, R, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (27.27) | 29.6817 |
| 2010's | 27 (49.09) | 24.3611 |
| 2020's | 13 (23.64) | 2.80 |
| Authors | Studies |
|---|---|
| Dehmel, F | 1 |
| Ciossek, T | 1 |
| Maier, T | 1 |
| Weinbrenner, S | 1 |
| Schmidt, B | 1 |
| Zoche, M | 1 |
| Beckers, T | 1 |
| Fournier, JF | 1 |
| Bhurruth-Alcor, Y | 1 |
| Musicki, B | 1 |
| Aubert, J | 1 |
| Aurelly, M | 1 |
| Bouix-Peter, C | 1 |
| Bouquet, K | 1 |
| Chantalat, L | 1 |
| Delorme, M | 1 |
| Drean, B | 1 |
| Duvert, G | 1 |
| Fleury-Bregeot, N | 1 |
| Gauthier, B | 1 |
| Grisendi, K | 1 |
| Harris, CS | 1 |
| Hennequin, LF | 1 |
| Isabet, T | 1 |
| Joly, F | 1 |
| Lafitte, G | 1 |
| Millois, C | 1 |
| Morgentin, R | 1 |
| Pascau, J | 1 |
| Piwnica, D | 1 |
| Rival, Y | 1 |
| Soulet, C | 1 |
| Thoreau, É | 1 |
| Tomas, L | 1 |
| Grimm, SE | 1 |
| Witlox, W | 1 |
| Wolff, R | 1 |
| Chalker, A | 1 |
| Hiligsmann, M | 1 |
| Wijnen, B | 1 |
| Ahmadu, C | 1 |
| Ryder, S | 1 |
| Armstrong, N | 1 |
| Duffy, S | 1 |
| Syndikus, I | 1 |
| Kleijnen, J | 1 |
| Joore, MA | 1 |
| Fujii, K | 2 |
| Idogawa, M | 1 |
| Suzuki, N | 1 |
| Iwatsuki, K | 2 |
| Kanekura, T | 2 |
| Hawkins, N | 1 |
| Muszbek, N | 1 |
| Evans, R | 1 |
| Dequen-O'Byrne, P | 1 |
| Jones, T | 1 |
| McNamara, L | 1 |
| Beylot-Barry, M | 2 |
| Booken, N | 1 |
| Weishaupt, C | 1 |
| Scarisbrick, J | 2 |
| Wu, W | 1 |
| Rosen, JP | 1 |
| Medley, MC | 1 |
| Papadopoulou, V | 1 |
| Degrauwe, N | 1 |
| Decosterd, LA | 1 |
| Buclin, T | 1 |
| Cairoli, A | 1 |
| Bordeaux, ZA | 1 |
| Reddy, SV | 1 |
| Lee, K | 1 |
| Lu, W | 1 |
| Choi, J | 1 |
| Miller, M | 1 |
| Roberts, C | 1 |
| Pollizzi, A | 1 |
| Kwatra, SG | 1 |
| Kwatra, MM | 1 |
| Ikumi, N | 1 |
| Fujita, H | 2 |
| Terui, T | 1 |
| Takahashi, H | 1 |
| Miura, K | 1 |
| Hatta, Y | 1 |
| Takei, M | 1 |
| Gluud, M | 1 |
| Fredholm, S | 1 |
| Blümel, E | 1 |
| Willerslev-Olsen, A | 1 |
| Buus, TB | 1 |
| Nastasi, C | 1 |
| Krejsgaard, T | 1 |
| Bonefeld, CM | 1 |
| Woetmann, A | 1 |
| Iversen, L | 1 |
| Litman, T | 1 |
| Geisler, C | 1 |
| Ødum, N | 1 |
| Lindahl, LM | 1 |
| Ellis, A | 1 |
| Christensen, LF | 1 |
| Sharma, T | 1 |
| Meyerson, H | 1 |
| Kord, H | 1 |
| Cooper, KD | 1 |
| Gassenmaier, M | 1 |
| Rentschler, M | 1 |
| Fehrenbacher, B | 1 |
| Eigentler, TK | 1 |
| Ikenberg, K | 1 |
| Kosnopfel, C | 1 |
| Sinnberg, T | 1 |
| Niessner, H | 1 |
| Bösmüller, H | 1 |
| Wagner, NB | 1 |
| Schaller, M | 1 |
| Garbe, C | 1 |
| Röcken, M | 1 |
| Porcu, P | 2 |
| Hudgens, S | 1 |
| Horwitz, S | 2 |
| Quaglino, P | 1 |
| Cowan, R | 1 |
| Geskin, L | 2 |
| Floden, L | 1 |
| Bagot, M | 2 |
| Tsianakas, A | 1 |
| Moskowitz, A | 1 |
| Huen, A | 1 |
| Dreno, B | 2 |
| Dalle, S | 1 |
| Caballero, D | 1 |
| Leoni, M | 1 |
| Dale, S | 1 |
| Herr, F | 1 |
| Duvic, M | 5 |
| Jimura, N | 1 |
| Qiao, Z | 1 |
| Tsuchiya, R | 1 |
| Yoshimatsu, Y | 1 |
| Kondo, T | 1 |
| Basu, D | 1 |
| Salgado, CM | 1 |
| Bauer, B | 1 |
| Hoehl, RM | 1 |
| Moscinski, CN | 1 |
| Schmitt, L | 1 |
| Reyes-Múgica, M | 1 |
| Zinzani, PL | 1 |
| Kim, YH | 2 |
| Moskowitz, AJ | 1 |
| Dwyer, K | 1 |
| Sun, W | 1 |
| Herr, FM | 1 |
| Ragheb, R | 1 |
| Venton, G | 1 |
| Chelbi, R | 1 |
| Bonnet, N | 1 |
| Le Treut, T | 1 |
| Ivanov, V | 1 |
| Mercier, C | 1 |
| Poulin, P | 1 |
| Beaufils, N | 1 |
| Gabert, J | 1 |
| Suchon, P | 1 |
| Rihet, P | 1 |
| Loriod, B | 1 |
| Kahn-Perlès, B | 1 |
| Costello, RT | 1 |
| Malone, DC | 1 |
| Numata, T | 1 |
| Nagatani, T | 1 |
| Shirai, K | 1 |
| Maeda, T | 1 |
| Mae, K | 1 |
| Nakasu, M | 1 |
| Saito, M | 1 |
| Usuda, T | 1 |
| Tsuboi, R | 2 |
| Okubo, Y | 1 |
| Wang, L | 2 |
| Leite de Oliveira, R | 1 |
| Huijberts, S | 1 |
| Bosdriesz, E | 1 |
| Pencheva, N | 1 |
| Brunen, D | 1 |
| Bosma, A | 1 |
| Song, JY | 1 |
| Zevenhoven, J | 1 |
| Los-de Vries, GT | 1 |
| Horlings, H | 1 |
| Nuijen, B | 1 |
| Beijnen, JH | 1 |
| Schellens, JHM | 1 |
| Bernards, R | 1 |
| Kasamon, YL | 1 |
| Chen, H | 1 |
| de Claro, RA | 1 |
| Nie, L | 1 |
| Ye, J | 1 |
| Blumenthal, GM | 1 |
| Farrell, AT | 1 |
| Pazdur, R | 2 |
| Haas, NB | 1 |
| Quirt, I | 1 |
| Hotte, S | 1 |
| McWhirter, E | 1 |
| Polintan, R | 1 |
| Litwin, S | 1 |
| Adams, PD | 1 |
| McBryan, T | 1 |
| Martin, LP | 1 |
| vonMehren, M | 1 |
| Alpaugh, RK | 1 |
| Zweibel, J | 1 |
| Oza, A | 1 |
| Kogge, A | 1 |
| Volteau, C | 1 |
| Saint-Jean, M | 1 |
| Peuvrel, L | 1 |
| Brocard, A | 1 |
| Knol, AC | 1 |
| Renaut, JJ | 1 |
| Quéreux, G | 1 |
| Humme, D | 1 |
| Nast, A | 1 |
| Erdmann, R | 1 |
| Vandersee, S | 1 |
| Beyer, M | 2 |
| Miyagaki, T | 2 |
| Sugaya, M | 3 |
| Oka, T | 1 |
| Sato, S | 1 |
| Cedeno-Laurent, F | 1 |
| Singer, EM | 1 |
| Wysocka, M | 1 |
| Benoit, BM | 1 |
| Vittorio, CC | 3 |
| Kim, EJ | 3 |
| Yosipovitch, G | 1 |
| Rook, AH | 3 |
| Ritter, C | 1 |
| Fan, K | 1 |
| Paulson, KG | 1 |
| Nghiem, P | 1 |
| Schrama, D | 1 |
| Becker, JC | 1 |
| Uehara, J | 1 |
| Honma, M | 1 |
| Ohishi, Y | 1 |
| Ishida-Yamamoto, A | 1 |
| Abe, F | 1 |
| Kitadate, A | 1 |
| Ikeda, S | 1 |
| Yamashita, J | 1 |
| Nakanishi, H | 1 |
| Takahashi, N | 1 |
| Asaka, C | 1 |
| Teshima, K | 1 |
| Tagawa, H | 1 |
| Moyal, L | 1 |
| Yehezkel, S | 1 |
| Gorovitz, B | 1 |
| Keren, A | 1 |
| Gilhar, A | 1 |
| Lubin, I | 1 |
| Sherman, S | 1 |
| Hodak, E | 1 |
| Klemke, CD | 1 |
| Goerdt, S | 1 |
| Gardner, JM | 2 |
| Introcaso, CE | 1 |
| Nasta, SD | 1 |
| Evans, KG | 1 |
| Goldstein, S | 1 |
| Anderson, KA | 1 |
| Bartell, HL | 1 |
| Olsen, EA | 3 |
| Breneman, D | 1 |
| Pacheco, TR | 2 |
| Parker, S | 2 |
| Vonderheid, EC | 1 |
| Abuav, R | 1 |
| Ricker, JL | 2 |
| Rizvi, S | 1 |
| Chen, C | 2 |
| Boileau, K | 1 |
| Gunchenko, A | 1 |
| Sanz-Rodriguez, C | 1 |
| Geskin, LJ | 1 |
| Wozniak, MB | 1 |
| Villuendas, R | 1 |
| Bischoff, JR | 1 |
| Aparicio, CB | 1 |
| Martínez Leal, JF | 1 |
| de La Cueva, P | 1 |
| Rodriguez, ME | 1 |
| Herreros, B | 1 |
| Martin-Perez, D | 1 |
| Longo, MI | 1 |
| Herrera, M | 1 |
| Piris, MA | 1 |
| Ortiz-Romero, PL | 1 |
| Kavanaugh, SM | 1 |
| Kavanaugh, SA | 1 |
| White, LA | 1 |
| Kolesar, JM | 1 |
| Farley-Loftus, R | 1 |
| Mandal, R | 1 |
| Latkowski, JA | 1 |
| Aldabagh, B | 1 |
| Patel, RR | 1 |
| Honda, K | 1 |
| Wada, H | 1 |
| Kato, Y | 1 |
| Tobinai, K | 1 |
| Hamada, T | 1 |
| Shimamoto, T | 1 |
| Noguchi, K | 1 |
| Al-Yacoub, N | 1 |
| Fecker, LF | 1 |
| Möbs, M | 1 |
| Plötz, M | 1 |
| Braun, FK | 1 |
| Sterry, W | 2 |
| Eberle, J | 1 |
| Gowda, R | 1 |
| Madhunapantula, SV | 1 |
| Desai, D | 1 |
| Amin, S | 1 |
| Robertson, GP | 1 |
| Lynch, DR | 1 |
| Washam, JB | 1 |
| Newby, LK | 1 |
| Kakizaki, A | 1 |
| Fujimura, T | 1 |
| Mizuashi, M | 1 |
| Watabe, A | 1 |
| Kambayashi, Y | 1 |
| Aiba, S | 1 |
| Kurundkar, D | 1 |
| Srivastava, RK | 1 |
| Chaudhary, SC | 1 |
| Ballestas, ME | 1 |
| Kopelovich, L | 1 |
| Elmets, CA | 1 |
| Athar, M | 1 |
| Grant, S | 1 |
| Easley, C | 1 |
| Kirkpatrick, P | 1 |
| Parker, SR | 1 |
| Bradley, B | 1 |
| Kuzel, TM | 1 |
| Foss, FM | 1 |
| Frankel, SR | 2 |
| Arduino, JM | 1 |
| Scheinfeld, N | 1 |
| Mann, BS | 1 |
| Johnson, JR | 1 |
| Cohen, MH | 1 |
| Justice, R | 1 |
| Fantin, VR | 1 |
| Loboda, A | 1 |
| Paweletz, CP | 1 |
| Hendrickson, RC | 1 |
| Pierce, JW | 1 |
| Roth, JA | 1 |
| Li, L | 1 |
| Gooden, F | 1 |
| Korenchuk, S | 1 |
| Hou, XS | 1 |
| Harrington, EA | 1 |
| Randolph, S | 1 |
| Reilly, JF | 1 |
| Ware, CM | 1 |
| Kadin, ME | 1 |
| Richon, VM | 1 |
| Steinhoff, M | 1 |
| Roewert-Huber, J | 1 |
| Lukowsky, A | 1 |
| Assaf, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Vorinostat in Patients With Advanced Melanoma[NCT00121225] | Phase 2 | 32 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers[NCT00907738] | Phase 2 | 27 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Phase I Clinical Study of MK-0683 in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)[NCT00771472] | Phase 1 | 10 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma[NCT00091559] | Phase 2 | 74 participants (Actual) | Interventional | 2005-02-03 | Completed | ||
| A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Blood specimens were collected from participants on Day 1 Cycle 1 prior to treatment (baseline), Day 1 3-4 hours following Vorinostat ingestion, Day 8 and Day 15. VEGF serum concentrations were detected using the Luminex multiplexed assay, where the median fluorescence intensity results were analyzed by a weighted five-parameter logistic method. The values were averaged across all time points per participant. (NCT00121225)
Timeframe: Baseline, Day 1, Day 8 and Day 15
| Intervention | pg (Mean) |
|---|---|
| Arm 1 Vorinostat | 203 |
Per Response Evaluation Criteria in Solid Tumours Criteria (RECIST v1.0) for target lesions and are assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), at least 30% decrease in sum of longest diameter of target lesions; Objective Response (OR) = CR+ PR. (NCT00121225)
Timeframe: Up to 5 years
| Intervention | participants (Number) |
|---|---|
| Arm I | 2 |
(NCT00121225)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm 1 Vorinostat | 4 |
Macro H2A and HP1 expression levels were compared through analysis of log fold changes in antibody expression in a multivariate general linear model between progressive disease and stable disease outcomes. (NCT00121225)
Timeframe: Baseline and day 15
| Intervention | log fold change (Mean) | ||
|---|---|---|---|
| MacroH2A1.1 | MacroH2A1.2 | HP1 | |
| Arm 1 Vorinostat | 0.149 | -0.748 | -0.077 |
Participants were assessed for p53 allelic variation at baseline (NCT00121225)
Timeframe: Baseline
| Intervention | participants (Number) | |
|---|---|---|
| Wild Type | Mutant | |
| Arm 1 Vorinostat | 20 | 11 |
"A serious adverse event (SAE) was any AE occurring at any dose that resulted in death, was life-threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a cancer, or was an overdose.~A drug-related SAE was one that was thought to be possibly, probably, or definitely related to the study drug." (NCT00907738)
Timeframe: From the first dose of study drug until the patient experiences disease progression, withdraws consent, or develops unacceptable toxicity (from Day 1 up to 4 years and 9 months)
| Intervention | percent of participants (Number) |
|---|---|
| Base Protocol 001 | 7.7 |
| Base Protocol 006 | 0 |
| Base Protocol 008 | 0 |
| Base Protocol 012 | 0 |
| Base Protocol 013 | 0 |
"A DLT was defined as any of the following (per Common Terminology Criteria for Adverse Events [CTCAE] version 3.0):~Grade 3 (severe)-4 (life-threatening) neutropenia with fever ≥ 38.5ºC~Grade 3-4 neutropenia with an infection requiring antibiotic or antifungal treatment~Grade 4 neutropenia lasting at least 5 days~Grade 4 thrombocytopenia~Other Grade 4 hematologic toxicity, including a decrease in hemoglobin, only at the discretion of the principal investigator~Grade 3 or 4 non-hematologic event, except which are manageable by supportive care or non-prohibited therapies" (NCT00771472)
Timeframe: Day 1 to Day 28
| Intervention | participants (Number) |
|---|---|
| Vorinostat | 1 |
"Blood samples taken as follows:~Day 1 & Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat." (NCT00771472)
Timeframe: Days 1 & 28 of Cycle 1
| Intervention | µM (Geometric Mean) | |
|---|---|---|
| Day 1 (n=6) | Day 28 (n=5) | |
| Vorinostat | 0.83 | 1.17 |
"Blood samples taken as follows:~Day 1 & Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat." (NCT00771472)
Timeframe: Days 1 & 28 of Cycle 1
| Intervention | hours (Geometric Mean) | |
|---|---|---|
| Day 1 (n=5) | Day 28 (n=4) | |
| Vorinostat | 1.94 | 2.30 |
"Blood samples taken as follows:~Day 1 & Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat." (NCT00771472)
Timeframe: Days 1 & 28 of Cycle 1
| Intervention | hours (Median) | |
|---|---|---|
| Day 1 (n=6) | Day 28 (n=5) | |
| Vorinostat | 2.91 | 3.73 |
"Blood samples taken as follows:~Day 1 & Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat." (NCT00771472)
Timeframe: Days 1 & 28 of Cycle 1
| Intervention | µM*hr (Geometric Mean) | |
|---|---|---|
| Day 1 (n=6) | Day 28 (n=5) | |
| Vorinostat | 4.59 | 5.59 |
A laboratory AE is defined as any unfavorable & unintended change in the chemistry of the body temporally associated with the use of study product, whether or not considered related to the use of the product. A clinical AE is defined similarly but also includes changes in structure or function of the body. (NCT00771472)
Timeframe: Day 1 up until 30 days post study completion or early termination (up to approximately 506 days)
| Intervention | participants (Number) | |
|---|---|---|
| Clinical AEs | Laboratory AEs | |
| Vorinostat | 10 | 6 |
9 reviews available for vorinostat and Cancer of Skin
| Article | Year |
|---|---|
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adult; Antibodies, Monoclonal, Humanized; Bexarotene; Cost-Benefit Analysis; Humans; Mycosis Fungoid | 2022 |
Systematic review of combination therapies for mycosis fungoides.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Deoxycytidine | 2014 |
Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Topics: Depsipeptides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lymphoma, T-Cell, | 2015 |
Molecular biology and targeted therapy of cutaneous T-cell lymphomas.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antige | 2008 |
Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Histone Deacetylase Inhibitors; Humans; Hydroxamic | 2010 |
QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature.
Topics: Antineoplastic Agents; Doxepin; Electrocardiography; Histone Deacetylase Inhibitors; Humans; Hydroxa | 2012 |
Treatment of cutaneous T-cell lymphoma/mycosis fungoides.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antineoplastic Agents; Bexarotene; Biopsy; Cost | 2006 |
Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine | 2007 |
A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bexarotene; Diphtheria Toxin; Drug Approv | 2007 |
10 trials available for vorinostat and Cancer of Skin
| Article | Year |
|---|---|
Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome.
Topics: Humans; Mycosis Fungoides; Sezary Syndrome; Skin Neoplasms; Vorinostat | 2022 |
Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.
Topics: Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Syndrome; Skin Neoplasms; Vorinostat | 2023 |
Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Female; Humans; Male; Middle Aged; Minimal Clinically Impor | 2021 |
Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
Topics: Antibodies, Monoclonal, Humanized; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Sy | 2021 |
FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Drug Approval; Drug Resistance, N | 2019 |
Phase II trial of vorinostat in advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Disease-Free Survival; Female; Fi | 2014 |
Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
Topics: Aged; Antineoplastic Agents; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymph | 2009 |
Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Histone Deacetylase Inhibitors; Humans; Hydroxamic | 2012 |
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Confidence Intervals; Dose-Response Relationsh | 2007 |
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relations | 2007 |
36 other studies available for vorinostat and Cancer of Skin
| Article | Year |
|---|---|
Trithiocarbonates: exploration of a new head group for HDAC inhibitors.
Topics: Carbon; Carbonates; Chemistry, Pharmaceutical; Drug Design; Enzyme Inhibitors; Histone Deacetylase I | 2007 |
Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Dose | 2018 |
Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gene | 2021 |
Simultaneous kinetics of oral vorinostat in plasma and cerebrospinal fluid in a patient with cutaneous T-cell lymphoma with CNS involvement.
Topics: Antineoplastic Agents; Humans; Kinetics; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms; Vorinostat | 2023 |
Differential Response of Mycosis Fungoides Cells to Vorinostat.
Topics: Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Proteomics; Skin Neoplasms; Vorinostat | 2023 |
Aggressive CD4-CD8-CD45RA+CCR10- Primary Cutaneous Peripheral T-cell Lymphoma, Not Otherwise Specified: A Case Report.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; CD4 Antigens; CD8 Antigens; Disease Progression; Fat | 2019 |
MicroRNA-93 Targets p21 and Promotes Proliferation in Mycosis Fungoides T Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; | 2021 |
CD30
Topics: Aged; Bexarotene; Humans; Ki-1 Antigen; Male; Middle Aged; Mycosis Fungoides; Photopheresis; Sezary | 2021 |
Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors.
Topics: Cell Line, Tumor; Cell Proliferation; DNA; Histone Deacetylase Inhibitors; Humans; Melanocytes; Mela | 2020 |
Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Depsipeptides; Drug Scr | 2021 |
Histone deacetylase inhibitor Vorinostat (SAHA) suppresses micropthalmia transcription factor expression and induces cell death in nevocytes from large/giant congenital melanocytic nevi.
Topics: Cell Death; Cell Differentiation; Child, Preschool; Histone Deacetylase Inhibitors; Humans; Infant; | 2021 |
Vorinostat and Mithramycin A in combination therapy as an interesting strategy for the treatment of Sézary T lymphoma: a transcriptomic approach.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Therapy, Combination; Gene Expression Regulation, Neop | 2017 |
An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma.
Topics: Antineoplastic Agents; Bexarotene; Cost-Benefit Analysis; Diphtheria Toxin; Humans; Hydroxamic Acids | 2018 |
Sézary syndrome managed with histone deacetylase inhibitor followed by anti-CCR4 monoclonal antibody.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Histone Deacetylase Inhibitors; Huma | 2018 |
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.
Topics: Amino Acid Transport System y+; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resis | 2018 |
Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Histone | 2015 |
Serum chemokine levels differentially regulated by vorinostat in a Sézary syndrome patient.
Topics: Antineoplastic Agents; Chemokines; Female; Humans; Hydroxamic Acids; Middle Aged; Sezary Syndrome; S | 2015 |
Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.
Topics: Adult; Aged; Aged, 80 and over; Depsipeptides; Dexamethasone; Female; Histone Deacetylase Inhibitors | 2015 |
Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma.
Topics: Acetylation; Animals; Carcinoma, Merkel Cell; Cell Line, Tumor; Cytotoxicity, Immunologic; Gene Sile | 2016 |
Successful combination therapy of low-dose vorinostat, etretinate and narrowband ultraviolet B irradiation for Sézary syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etretinate; Female; Human | 2017 |
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Female; Gene Expression Regulation, | 2017 |
Oncogenic role of microRNA-155 in mycosis fungoides: an in vitro and xenograft mouse model study.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Female; Genes, cdc; HEK293 Cells; Hete | 2017 |
A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome.
Topics: Aged, 80 and over; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic | 2009 |
Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma.
Topics: Antibodies, Anti-Idiotypic; Antineoplastic Agents; Diagnosis, Differential; Dose-Response Relationsh | 2009 |
Leukonychia related to vorinostat.
Topics: Adult; Aged; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Male; Mycos | 2009 |
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cell Proliferat | 2010 |
Poikilodermatous mycosis fungoides.
Topics: Acitretin; Antineoplastic Agents; Bexarotene; Female; Humans; Hydroxamic Acids; Hypopigmentation; Im | 2010 |
Leukemia cutis in association With Grover's disease.
Topics: Acantholysis; Aged; Antineoplastic Agents; Biopsy; Dermis; Fatal Outcome; Flavonoids; Humans; Hydrox | 2011 |
Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; CASP8 and FADD-Like Apoptosis Regulating Protein; Do | 2012 |
Selenium-containing histone deacetylase inhibitors for melanoma management.
Topics: Anilides; Anticarcinogenic Agents; Apoptosis; Caspase 3; Caspase 7; Cell Cycle Checkpoints; Cell Lin | 2012 |
Successful treatment of syringotropic CD8+ mycosis fungoides accompanied by hypohidrosis with vorinostat and retinoids.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CD8 Antigens; Humans; Hydroxamic Acids; Hypoh | 2013 |
Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Cell Surviv | 2013 |
Vorinostat.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Drug Approval; D | 2007 |
Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Histone Deacetylase Inhibitors; Humans; Hydroxamic | 2007 |
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neo | 2008 |
Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate.
Topics: Acute Disease; Anticarcinogenic Agents; Bexarotene; Biopsy; Drug Eruptions; Female; Fenofibrate; Fev | 2008 |